Key Takeaways

  • VeonGen reached FDA alignment on pivotal phase 3 trial design and manufacturing considerations for VG801

  • In phase 1/2 testing, 11 of 13 evaluable patients achieved BCVA gains of at least 5 ETDRS letters at Month 6 or Month 12

  • VG801 uses a dual-AAV platform designed to deliver a functional ABCA4 gene, potentially addressing multiple Stargardt disease genotypes

VeonGen Therapeutics announced regulatory progress for VG801, its investigational dual-adeno-associated virus (AAV) gene therapy for Stargardt disease and other ABCA4-associated retinal dystrophies, including FDA alignment on key aspects of its planned pivotal phase 3 trial.

During a Regenerative Medicine Advanced Therapy (RMAT) Type B meeting, the FDA and VeonGen reached alignment on the phase 3 study design, including the primary endpoint, study duration, and control arm. The agency also agreed on key chemistry, manufacturing, and controls considerations, including use of the existing clinical batch for the pivotal study and elements of the commercial manufacturing strategy.

The company is also advancing its Virtual Reality Visual Test (VRVT) through the FDA's Rare Disease Endpoint Advancement Pilot Program as a potential functional vision endpoint. Phase 1/2 clinical trial authorizations have been obtained in Europe and China.

The ongoing first-in-human phase 1/2 study (NCT07002398) has enrolled and dosed 15 adult and pediatric patients across 3 dose cohorts.

According to company-reported findings, all 13 patients with measurable baseline best-corrected visual acuity (BCVA) demonstrated improvement at Month 6 or Month 12. Eleven patients gained at least 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, including 7 who gained at least 10 letters, and 4 who gained at least 15 letters.

VeonGen also reported sustained improvements through Month 12 across VRVT and microperimetry fixation assessments, with stable retinal structures and a favorable safety profile to date.

“FDA alignment on the pivotal phase 3 clinical and CMC strategy represents an important de-risking milestone for VG801 and a significant step toward global pivotal development,” said Caroline Man Xu, MD, cofounder and chief executive officer of VeonGen Therapeutics.

VG801 combines the company's vgAAV2 capsid technology with its vgRNA REVeRT platform to deliver and reconstitute a full-length functional human ABCA4 gene in retinal photoreceptor cells. The dual-AAV approach is designed to address Stargardt disease across different ABCA4 mutations.

VG801 has received FDA RMAT, Rare Pediatric Disease, and Orphan Drug designations.